China has about 30 million patients with chronic hepatitis B. According to the survey, the number of patients receiving standardized antiviral treatment is less than 30%. The “concept” and “therapy” are very deceptive and deceptive, leading patients to try their bodies with different amounts of money, resulting in no success, and the people and money. 2, some patients although antiviral treatment, but do not understand the long-term nature of antiviral treatment, the medication course is not enough, or with stop, resulting in treatment failure, it is regrettable. 3.Some patients cannot adhere to the correct health care concept of long-term follow-up and regular monitoring, thus they also miss the opportunity of antiviral treatment again and again, and some of them are found to be cirrhosis and liver cancer. 4, some clinicians have old concepts and knowledge, and only recommend the use of liver-protective drugs and immunomodulatory drugs with inaccurate efficacy to patients. The standardized treatment of chronic hepatitis B is to achieve control of disease progression, improve the degree of liver inflammation and fibrosis, prevent and slow down the occurrence of cirrhosis and hepatocellular carcinoma, prolong survival time and improve quality of life through effective antiviral. How to implement the standardized treatment of chronic hepatitis B? The first thing to do is to choose a regular hospital hepatitis specialist. Hepatitis specialists in regular hospitals are not only equipped with specialist physicians, but also have a complete set of equipment for diagnosing viral hepatitis and monitoring the effectiveness of treatment. In addition, the specialist physician to determine the effectiveness of hepatitis treatment is not based on the patient’s subjective feelings alone, but combined with objective laboratory and examination results, and sometimes even need laboratory tests, dynamic observation and testing of some important indicators to make a scientific judgment, in order to correctly develop or adjust the treatment plan for patients. Chronic hepatitis B is characterized by a long duration and often recurrent disease. Another characteristic is that the patient’s symptoms, laboratory results sometimes do not have a parallel relationship with the actual degree of liver cell damage, i.e. sometimes the liver tissue examination is more obvious, while the patient’s self-perception is not. In this case, it is more important to have a clinically experienced hepatitis specialist to grasp the actual situation of the lesion. This is why we regard the choice of hospital and specialist as the first step in the correct standardized treatment of chronic hepatitis B patients. If you make a mistake in this step, it is inevitable that you will not be able to take the right steps or even go further and further in the future. The second goal of treatment is to block hepatitis B virus replication. The replication (reproduction) of the hepatitis B virus in the body is an important cause of recurrent disease. If the virus replication is at a high level, it mostly manifests as heavy hepatitis (when hospitalization is required); at a low level, the symptoms are not obvious but the liver has recurrent inflammatory damage and repair processes. These two processes often recur, causing the disease to progress to liver fibrosis and cirrhosis. Therefore, blocking hepatitis B virus replication is the fundamental aim of chronic hepatitis B treatment. Standardized antiviral therapy can have at least five benefits: 1. inhibit viral replication; 2. reduce infectiousness; 3. improve liver function; 4. reduce liver tissue damage; 5. reduce or stop liver fibrosis and liver cancer caused by cirrhosis; and improve quality of life. Treatment protocols emphasize individualization of medications. Chronic hepatitis B is a complex and diverse condition with inconsistent severity and presentation, as well as individual differences in the route of infection, gender, age, genetic background, duration of disease, degree of liver disease, sensitivity to therapeutic drugs, tolerance to adverse drug reactions, viral genes, and many other factors, requiring individualized treatment by specialist physicians according to the patient’s specific situation. For patients with chronic hepatitis B who are first diagnosed, the specialist will select antiviral drugs based on the various factors mentioned above. After 3-6 months of observation of the efficacy, adjustments in drugs and doses may be required so that each patient’s treatment plan is more appropriate to his or her actual situation and needs. If the patient voluntarily abandons regular follow-up, the specialist will not be able to systematically observe changes in the disease and will not be able to adjust the treatment plan in a timely manner, which is not conducive to achieving a stable and lasting treatment effect.